Merck Animal Health Gets USDA Approval for Landmark Poultry Vaccine INNOVAX® ND-IBD-ILT

Merck Animal Health (known as MSD Animal Health outside the United States and Canada), a division of Merck & Co., Inc. (NYSE: MRK), announced that the U.S. Department of Agriculture (USDA) has approved INNOVAX® ND-IBD-ILT.

The approval marks the commercial launch of the first recombinant vaccine capable of protecting poultry against four major viral diseases—Newcastle Disease (ND), Infectious Bursal Disease (IBD), Infectious Laryngotracheitis (ILT), and Marek’s Disease (MD)—in a single hatchery administration.

The vaccine is scheduled for commercial availability across the United States in the fourth quarter of 2026.

Detailed Summary Breakdown

Strategic Significance & Executive Commentary

Poultry producers globally face expanding biosecurity demands, labor shortages, and complex vaccination protocols. Managing multiple individual immunizations for Newcastle Disease, Bursal Disease, Laryngotracheitis, and Marek’s Disease historically required repeated live-virus farm treatments or multiple hatchery injections, increasing operational labor and bird handling stress.

By consolidating protection into a single hatchery dose, INNOVAX® ND-IBD-ILT simplifies flock management while safeguarding flock welfare and metabolic growth performance.

“Poultry producers and veterinarians need disease protection that is both comprehensive and practical. By helping protect against four major diseases in a single hatchery vaccination, INNOVAX ND-IBD-ILT reduces complexity and provides veterinarians with greater convenience throughout the production cycle.”

— Charles Broussard, D.V.M., Senior Account Manager for Poultry Sales, Merck Animal Health

Biotechnology & Disease Protection Overview

INNOVAX® ND-IBD-ILT leverages a recombinant turkey herpesvirus (HVT) vector base engineered with dual glycoprotein inserts (gD and gI) alongside target antigens. This dual-insert technology stimulates robust cellular and humoral immune responses against ILT while maintaining long-term efficacy against ND, IBD, and Marek’s Disease.

Detailed Pathogen & Impact Breakdown

• Newcastle Disease (ND Virus)

  • Primary Target Systems: Respiratory, nervous, and digestive tracts.

  • Clinical Impact: Prevents severe respiratory distress, drop in egg production, systemic metabolic reactions, and mortality.

• Infectious Bursal Disease (IBD / Gumboro)

  • Primary Target Organ: Target tissues within the Bursa of Fabricius.

  • Clinical Impact: Protects against standard and variant IBD field strains, preventing bursal atrophy and immune depletion.

• Infectious Laryngotracheitis (ILT)

  • Primary Target Systems: Upper respiratory tract and trachea.

  • Clinical Impact: Reduces severe upper respiratory distress, gasping, hemorrhagic tracheal lesions, and prevents live-vaccine-induced outbreaks.

• Marek’s Disease (MDV)

  • Primary Target Systems: T-cells, peripheral nervous system, and internal organs.

  • Clinical Impact: Prevents viral T-cell lymphomas, paralysis, visceral tumor development, and severe immunosuppression.

Vaccine Specification & Operational Summary

Industry & Economic Impact

• Reduced Handling Stress: Eliminates the need for post-hatch field boosts for ILT and ND, minimizing bird handling and avoiding metabolic growth delays during critical early brooding periods.

• Labor Optimization: Consolidates multiple vaccine administrations into automated hatchery processes (in ovo or Day-1 subcutaneous), mitigating field labor expenses for poultry integrators.

• Biosecurity Consistency: Centralizing immunization in the strictly controlled hatchery environment ensures uniform dose delivery across entire bird populations.